CLINICAL ROLE -
Oral Oncology: Utilization of Selected Oral Antineoplastic Enzyme Inhibitor Agents
An overview of the utilization and cost for selected oral antineoplastic agents, with discussion regarding oncology in general, as well as the topic of adherence.
Prescription Utilization of the Oral Anticoagulants
New and forthcoming oral anticoagulants, which do not require prothrombin time monitoring, will offer patients and providers additional therapeutic options.
Initial Prescription Utilization of the New Hepatitis C Agents
Incivek and Victrelis, approved for Hepatitis C within weeks of each other in May 2011, look to change the way the disease is treated.
Early View of Ampyra and Gilenya Use by MS Patients
Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.
New Drugs, First Generics, and the Near-Term Pipeline 2012
Approvals of potential blockbuster drugs represent a new source of revenue for pharmaceutical manufacturers, who will experience significant income loss from generic competition in 2011-2012.
A Look Into 2011 Drug Utilization Trend and Beyond
Significant factors for 2011 prescription utilization include the recession, change in employment rate, new generic and brand launches, and changes in Baby Boomers' retirement plans.
Gaining Insight Into the 2010 Drug Trend and Beyond
The major impact on price trend was double-digit price increases in top brand drugs, offset by price erosion for both old and new generics.
Generic Drug Trends in the United States
By 2012, we estimate that more than 3 of every 4 prescriptions will be filled with a generic drug.
2010 Drug Utilization and Cost Trends for Antidiabetic Agents
The antihyperglycemic therapeutic class will continue to be a major contributor to prescription drug trends in 2011 and beyond.
2009 Drug Utilization and Cost Trends: Tumor Necrosis Factor Inhibitors
Specialty drugs are a significant cost trend driver for the majority of plan sponsors.
Proton Pump Inhibitor Drug Utilization and Cost Trends
Increased generic substitution is projected to erode prices and outpace
class utilization growth for proton pump inhibitors in 2010.
Generational Impact on Prescription Drug Trend: Part 2
This retrospective study of 558.9 million prescription claims explores how member age demographics affect prescription drug trends and provides top therapeutic classes by generation.
2009 Drug Utilization and Cost Trends in Lipid-Lowering Agents
The dispensing rate for generic statins is expected to rise slowly due to increased volumes of simvastatin and pravastatin sodium moderated
by increased Crestor volumes.
Antineoplastic Enzyme Inhibitor Drug Trend Utilization in the United States
Increases in the number of cancer cases being diagnosed and treated likely will drive cost trends for antineoplastic enzyme inhibitors.
Prescription Utilization by Multiple Sclerosis Patients in the United States
Future costs of MS therapy are likely to increase due to new add-on therapy combined with double-digit growth in utilization for existing drugs.
Drug Utilization Patterns in Patients With Alzheimer's Disease
The proportion of Americans diagnosed with Alzheimer's disease (AD) is projected to increase almost 2-fold over the next couple of decades due to size of the Baby Boom generation compared with the total US population.
Factors Affecting Pharmacy Trends in 2008
The increase in generic medications, changes in utilization patterns, and the significant decrease in the approval of new molecular entities have slowed 2008 pharmacy trends to historically low levels.
Recent Trends in Utilization of Antianxiety Medication
Although utilization of benzodiazepines is expected to continue to increase, overall class costs should remain low because of the availability of generics.
Generational Impact on Prescription Drug Trend: Part 1
Part 1 of this 2-part overview of prescription drug trend focuses on important therapeutic classes for all generations.
2 Clarke Drive Cranbury, NJ 08512